Author

Geert R. D'Haens 1

1 Amsterdam University Medical Center,Amsterdam,Netherlands

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Marla C. Dubinsky, Geert R. D'Haens, William J. Sandborn, Julian Panés, Chinyu Su, Nervin Lawendy, Irina Lazariciu, Sean Gardiner, Rajiv Mundayat, nicole kulisek, Irene Modesto, Siew C. Ng, Joana Torres

BASELINE HYPERTROPHY OF THE SUBMUCOSA AT INTESTINAL ULTRASOUND PREDICTS FAILURE OF TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Floris de Voogd, Cyriel Y. Ponsioen, Marjolijn Duijvestein, Mark Lowenberg, Krisztina Barbara Gecse, Geert R. D'Haens

CHARACTERIZATION OF CYTOKINE AND DRUG CONCENTRATIONS IN SERUM, MUCOSA AND FAECES DURING INDUCTION TREATMENT OF SEVERE ULCERATIVE COLITIS WITH INFLIXIMAB

Jurij Hanzel, Joep van Oostrom, Floris de Voogd, Sophie Berends, Johannan Frank Brandse, Sharat Singh, Jack Stylli, Jeffrey Smith, Geert R. D'Haens, Krisztina Barbara Gecse

COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL

Sangwook Yoon, Dong-Hyeon Kim, Fraser Cummings, Peter Irving, Geert R. D'Haens, Shomron Ben-Horin, Walter Reinisch, Byong Duk Ye, Stefan Schreiber

EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL

Peter Irving, Jean-Frédéric Colombel, Geert R. D'Haens, AnnKatrin Petersen, Denesh Chitkara, Cecilia Marta, Tianlei Chen, Lorna Charles, Silvio Danese, Subrata Ghosh

EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL

Geert R. D'Haens

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Geert R. D'Haens, Genoile O. Santana, William J. Sandborn, Irene Modesto, Chinyu Su, Nervin Lawendy, Jerome Paulissen, Marla C. Dubinsky, Miguel Regueiro, nicole kulisek, Sean Gardiner, Rajiv Mundayat, Joana Torres

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Geert R. D'Haens

Item 1 - 10 / 19
1
2